Objective-Naringenin is a citrus flavonoid that potently inhibits the assembly and secretion of apolipoprotein B100 -containing lipoproteins in cultured hepatocytes and improves the dyslipidemia and insulin resistance in a mouse model of the metabolic syndrome. In the present study, we used low-density lipoprotein receptor-null mice fed a high-fat diet (Western, TD96125) to test the hypothesis that naringenin prevents atherosclerosis. Methods and Results-Three groups (chow, Western, and Western plus naringenin) were fed ad libitum for 6 months. The
A therosclerotic lesions contribute to myocardial infarction and stroke and are responsible for cardiovascular disease developing into a principal cause of death in industrial societies. 1 Major risk factors for atherosclerosis include age, hypertension, diabetes mellitus, smoking, and dyslipidemia. Atherogenic dyslipidemia is characterized by increased plasma concentrations of triglyceride (TG)-rich very low-density lipoprotein (VLDL) and cholesterol-rich LDL and low levels of high-density lipoprotein. Plasma concentrations of apolipoprotein B100 (apoB100)-containing particles directly correlate with plasma cholesterol levels, making a reduction in apoB100 secretion an attractive therapeutic target.
The accumulation of cholesteryl ester (CE) within the arterial intima is an initiating factor in atherogenesis. 2 Its size and significant enrichment in CE characterize LDL as the most atherogenic lipoprotein. 3 Healthy vascular endothelium maintains a semipermeable barrier that prevents access to large molecules, including CE-rich LDL. 4 However, in response to injury, this barrier malfunctions, increases adhesiveness, and becomes more permeable, allowing LDL particles to enter and accumulate in the arterial intima. 5 On entry into the intima, LDL can be oxidized and scavenged by macrophages, resulting in the accumulation of lipoprotein-derived CE and foam cell formation. 6 However, LDL particles are not the only atherogenic lipoprotein. In vivo models with saturated or impaired chylomicron and VLDL clearance, such as animals fed diets high in fat and cholesterol or patients with type III hyperlipoproteinemia, demonstrate that remnants contribute significantly to atheroscle-rosis. 7, 8 Furthermore, increased concentrations of lipoprotein remnants are related to the progression of moderately sized lesions, which can predict coronary events. 9 Metabolic syndrome, a clustering of symptoms including dyslipidemia, hypertension, insulin resistance, and visceral obesity, represents an emerging risk factor for the development of type 2 diabetes and premature atherosclerosis. 10 Clinical trials have demonstrated the efficacy of statins in preventing cardiovascular events 11 ; however, the prevalence of metabolic syndrome and mixed dyslipidemia leaves many patients unable to meet lipid treatment targets while undergoing current therapy. 12, 13 Overproduction of VLDL is associated with insulin resistance, the metabolic syndrome, and type 2 diabetes; however, the mechanisms underlying VLDL overproduction are not completely understood. 14 -16 A major regulator of the assembly and secretion of apoB100-containing lipoproteins is lipid availability. 15, 16 Insulin resistance increases plasma free fatty acids (FFAs), hepatic de novo lipogenesis, and hepatic uptake of chylomicron remnant particles, all of which contribute to the hepatic TG secretory pool available for VLDL production. 16 Increased liver lipids have been associated with increased secretion of VLDL. 15 Current pharmacological therapies, primarily directed to cholesterol lowering, have little effect on liver TG accumulation, elevated plasma FFAs, or VLDL overproduction. 14 -16 Therefore, in the search for new and combination treatments for dyslipidemia in the setting of insulin resistance, interest in the protective role of naturally occurring polyphenolic compounds has emerged.
Epidemiological studies 17, 18 have established an inverse relationship between flavonoid consumption and coronary heart disease. Although much of this association has been attributed to their antioxidant properties, 19, 20 the lipid-lowering potential of polyphenols has also been evaluated. For example, berberine, an alkaloid isolated from Chinese herbs, upregulates LDL receptor (LDLR) activity in both human hepatoma (HepG2) cells and hyperlipidemic hamsters and reduces the LDL cholesterol (LDL-C) level in hypercholesterolemic patients. 21 The citrusderived flavonoid, naringenin, has lipid-lowering properties 22 ; and inhibits VLDL secretion from hepatocytes in a manner resembling insulin. [23] [24] [25] By using a mouse model that replicates many components of metabolic syndrome, Ldlr Ϫ/Ϫ mice fed a high-fat Western diet, we were able to show in studies of 4 weeks duration that the addition of naringenin to the Western diet prevented VLDL-apoB100 overproduction, ameliorated hepatic TG accumulation, and attenuated dyslipidemia. Through a reduction in both VLDL-derived and endogenously synthesized fatty acid, naringenin also prevented muscle lipid accumulation and attenuated the development of hyperinsulinemia. These factors led to improved overall insulin sensitivity and glucose tolerance. 26 Therefore, we hypothesized that in longer-term studies, naringenin would prevent the dyslipidemia and other metabolic disturbances linked to insulin resistance and the development of atherosclerosis.
In this study, we report that in Ldlr Ϫ/Ϫ mice fed ad libitum (ie, chow, Western, and Western plus naringenin) for 6 months, naringenin corrected dyslipidemia, hyperinsulinemia, and hepatic steatosis; prevented adipose accumulation; and markedly attenuated atherosclerosis by greater than 70% in both the aortic sinus and the aorta.
Methods

Animals and Diets
An expanded "Methods" section appears in a supplement (available online at http://atvb.ahajournals.org).
Male Ldlr Ϫ/Ϫ mice on the C57BL/6 background were obtained from the Jackson Laboratory, Bar Harbor, Me and housed in pairs in standard cages at 23°C. The animals were cared for in accordance with the Canadian Guide for the Care and Use of Laboratory Animals, and all experimental procedures were approved by the Animal Care Committee at the University of Western Ontario, London. Mice aged 10 to 12 weeks were fed the following ad libitum for 6 months: a purified rodent chow diet (4% of calories from fat; Harlan Teklad TD8604, Madison, Wis), a high-fat Western diet (42% of calories from fat and 0.05% cholesterol; Harlan Teklad TD96125), or the Western diet supplemented with 3% naringenin (wt/wt) (Sigma, St Louis, Mo) (Supplemental Table 1 ). In previous short-term studies, this dose resulted in a significant reduction in VLDL secretion, and correction of dyslipidemia, and insulin insensitivity. 26 The blood pressure and heart rate were assessed in conscious mice by the CODA system (Kent Scientific, Torrington, Conn). 27 Animals fasted for 6 hours before the intervention. Blood samples were obtained, 26 and the heart and aorta were excised as previously described. 28
Plasma and Tissue Lipid Determinations
Plasma TG, glycerol, total cholesterol, FFA, blood glucose, aspartate aminotransferase, and alanine aminotransferase levels were determined as previously described. 26 Interleukin 6 (R&D Systems, Minneapolis, Minn) and adiponectin and insulin (both from Alpco Diagnostics, Salem, NH) levels were obtained by ELISA on EDTAplasma, per the manufacturer's instructions. Fast-performance liquid chromatography (FPLC) was performed on unfrozen EDTA-plasma using a purifier (AKTA) and a column (Superose 6). Lipid levels were measured in the liver and unstained aortas. 29
Tissue Histology and Immunohistochemical Staining
For quantitation of lesion area in the aortic sinus, oil red O-stained sections were measured. Frozen serial sections of the aortic sinus, initiating at the origin of the aortic valves, were prepared using a cryostat (Leica CM 3050S). Slides were stained with modified Verhoff and Masson trichrome. Immunohistochemistry staining for macrophages by monocyte/macrophage antibody-2 (MOMA-2) (model MCA519G; Accurate, Westbury, NY) and smooth muscle cell (SMC) ␣-actin (Clone 1AH; Sigma) was performed as previously described. 30, 31 Full-length aortas were stained with fat-soluble dye (Sudan IV) and mounted with glycerol gelatin.
Statistical Analysis
All data are presented as the meanϮSEM. One-way ANOVA was used to determine the differences between groups, and pairwise comparisons were made by the Tukey test. PϽ0.05 is considered statistically significant.
Results
Naringenin Prevents Diet-Induced Weight Gain and Improves Dyslipidemia in High-Fat-Fed Ldlr ؊/؊ Mice
The metabolic effects of naringenin were evaluated in male C57BL/6 Ldlr Ϫ/Ϫ mice administered a Western diet containing 3% naringenin for 6 months. Western-fed mice gained significantly more weight than chow-fed mice. This weight gain was significantly attenuated by naringenin supplementation (Table) . Naringenin did not affect caloric intake (data not shown). The Western diet increased fasting plasma cholesterol (8-fold) and TG (5-fold) compared with the chow diet, whereas the addition of naringenin significantly decreased both lipids by 50% ( Figure 1A and B, respectively). FPLC analysis demonstrated that the Western diet increased levels of both VLDL-C and LDL-C relative to chow-fed mice. The addition of naringenin reduced VLDL-C and LDL-C, whereas high-density lipoprotein cholesterol was unaffected by any diet ( Figure 1C ). The Western diet also increased VLDL-TG compared with both chow-fed and naringenin-treated mice ( Figure 1D ). The area under the cholesterol curve demonstrated a 9-fold increase in both VLDL-C and LDL-C by the Western diet when compared with the chow diet, both of which were reduced by 60% with naringenin. The area under the VLDL-TG curve for Westernfed mice demonstrated a 2-fold increase, which was reduced 50% by naringenin. The Western diet induced extensive hepatic steatosis, with a 10-fold increase in both TG and CE mass compared with the chow diet. The addition of naringenin decreased both liver TG and CE mass by 80% ( Figure 1E and F, respectively). A significant increase in oil-red O-positive neutral lipid staining was observed in the liver from Western-fed animals, which was completely normalized by naringenin to levels observed in chow-fed mice ( Figure 1G ). None of the diets had a significant effect on plasma concentrations of liver enzymes (Table) . During the 6 months of study, no significant changes in blood pressure among any of the groups were observed (Table) .
Naringenin Prevents Hyperinsulinemia, Hyperglycemia, and Adipose Tissue Accumulation in High-Fat-Fed Ldlr ؊/؊ Mice
The modest hyperglycemia and the significant hyperinsulinemia that developed in Western-fed mice was normalized by naringenin to levels observed in chow-fed mice (Figure 2A and B, respectively). Naringenin also prevented elevations in plasma NEFA and glycerol (Table) . Naringenin decreased adipose tissue accumulation because the elevated adiposity index ( Table) and the adipocyte hypertrophy ( Figure 2C and D) observed in Western-fed mice were prevented. Despite differences in adipose tissue accumulation, there were no significant changes in plasma adiponectin or interleukin 6 concentrations among any of the diets (Table) .
Naringenin Prevents Atherosclerosis in Both the Aortic Sinus and En Face in High-Fat-Fed Ldlr ؊/؊ Mice
Atherosclerosis development in the aortic sinus was increased 10-fold in Western-fed mice compared with chow-fed animals. In naringenin-fed mice, lesion development was reduced by more than 70% ( Figure 3A ). Quantitation of fat-soluble dye-stained aortas, prepared en face, revealed that the Western diet increased plaque area 10-fold throughout the arch and abdominal sections of the aorta, compared with chow-fed mice ( Figure 3B and C). Aortic lesion area was significantly decreased by more than 70% (PϽ0.05) in naringenin-treated mice ( Figure 3B and C) . Lipid analysis of cleaned unstained aorta samples from Western-fed mice revealed a 4-fold increase in TG and a 6-fold increase in total Values with different letters are significantly different. cholesterol. Naringenin supplementation significantly decreased both TG and total cholesterol by 50% and 70%, respectively ( Figure 3D and E) . Immunohistochemistry analysis demonstrated infiltration of MOMA-2-positive leukocytes in lesions from all groups, which was associated with oil-red O-stained neutral lipid ( Figure 4A-C) . Although the total lesion area was significantly reduced in naringenin-treated animals ( Figures 3A and  4A and B), in plaques that did develop, morphometric analysis demonstrated a significant enrichment in MOMA-2positive staining. Trichrome staining revealed extensive collagen deposition in plaques from Western-fed animals, which was associated with SMC ␣-actin staining, indicating a fibrous phenotype ( Figure 4B and C) . In contrast, collagen deposition and the amount of SMC ␣-actin-positive cells were significantly less in lesions from naringenin-treated mice. Collectively, this morphometric analysis indicates that naringenin prevents the progression to a more complex lesion ( Figure 4B and C).
Discussion
Mice homozygous for Ldlr deficiency and fed a high-fat Western-style diet become dyslipidemic and insulin resistant and develop atherosclerosis. 32 Previously, it was demonstrated that the citrus flavonoid naringenin potently inhibits apoB100 secretion by activating signaling cascades in HepG2 cells, in a manner similar to insulin. [23] [24] [25] In contrast to insulin, signaling by naringenin occurs through a mechanism independent of phosphorylation of the insulin receptor. 24, 25 Recently, it was reported that naringenin sensitizes hepatocytes to respond to low doses of insulin and potentiates the inhibition of apoB100 secretion. 24 In a mouse model of insulin resistance (ie, the Western-fed Ldlr Ϫ/Ϫ mouse), the addition of naringenin to the high-fat diet over 4 weeks ameliorated the overproduction of apoB100-containing lipoproteins, attenuated hepatic lipid accumulation, and prevented dyslipidemia. 26 The major findings of this study are that 6-month supplementation of the Western diet with naringenin prevented hypercholesterolemia, hypertriglyceridemia, and hyperinsulinemia; and reduced hepatic steatosis. Collectively, the improvement in metabolic disturbances led to an overall 70% reduction in atherosclerosis within the aortic sinus and in en face aortic preparations. The extensive plaque in the aortic sinus of Western-fed mice was characterized by infiltration of both neutral lipid-rich macrophages and SMCs. Lesions in Western-fed animals also demonstrated increased collagen deposition, consistent with a more fibrillar plaque phenotype. 33 In contrast, naringenin treatment significantly de- creased lesion formation; and the lesions that did develop were much less advanced, as evidenced by reduced accumulation of SMCs and the deposition of elastin and collagen. These data demonstrate that naringenin prevents the development and progression of atherosclerosis in Ldlr Ϫ/Ϫ mice, induced by the Western diet.
In the Ldlr Ϫ/Ϫ mouse, the uptake of lipoprotein particles is impaired; and circulating lipid levels largely reflect hepatic and intestinal lipid pools. 34 The Western diet increases cholesterol and TG in both the VLDL and LDL fractions and increases lesion formation. Naringenin prevents the development of atherosclerosis in both the aorta and the aortic sinus, which is associated with a substantial reduction in VLDL and LDL-C. This observation is consistent with the findings of a recent study 35 in which VLDL-C concentrations were a strong predictor of atherosclerosis in the aortic sinus of Ldlr Ϫ/Ϫ mice fed a Western diet. Previous studies in highfat-fed Ldlr Ϫ/Ϫ mice demonstrated that hepatic cholesterol concentrations parallel plasma cholesterol levels. 36 The con-tribution of VLDL-C and LDL-C to cholesterol accumulation in the arterial wall may be related to the increased atherogenicity of acyl-coenzyme A: cholesterol acyltransferase 2 (ACAT2)-derived CE within apoB100-containing lipoprotein particles secreted by the liver. 37, 38 The inhibition of hepatic ACAT2 in apoB100-only Ldlr Ϫ/Ϫ mice results in marked reductions in VLDL-C and LDL-C and significant decreases in CE accumulation within the aorta. 39 In Ldlr Ϫ/Ϫ mice, after 4 weeks of feeding, naringenin decreased hepatic CE through a reduction in both cholesterol synthesis and esterification and decreased hepatic TG through increased FA oxidation, leading to reduced secretion of VLDL. 26 In the current study, the addition of naringenin to the Western diet decreased both hepatic CE and TG accumulation, which may limit the lipid available for VLDL production. Consistent with this observation, FPLC analysis of plasma from naringenin-fed mice showed a significant reduction in VLDL-C and LDL-C. Naringenin treatment significantly reduced aortic cholesterol by 64%, suggesting that the naringenin-induced decreases in hepatic CE, VLDL-C, and LDL-C translated to a reduction in cholesterol accumulation within the arterial wall and prevention of atherosclerosis.
Quantitation of atherosclerosis by oil-red O staining is a commonly used technique to examine lesion area; however, this stain cannot differentiate TG from CE within the plaque. In human lesions, TG is the least abundant lipid, making up approximately 9% of total lesion lipid; CE (52%), free cholesterol (25%), and phospholipid (14%) account for the remainder of lesion lipid. 40 In mouse models of severe hypertriglyceridemia and hypercholesterolemia, atherosclerosis development, as assessed by oil-red O staining, is increased compared with mice in which similar plasma cholesterol, but lower TG, levels are achieved. 32 This suggests that although CE-rich LDL particles are clearly atherogeneic, 3 in some models, TG may contribute significantly to the lesion area documented by staining. 35 In the aorta of Western-fed mice, TG (4-fold) and cholesterol (6-fold) increased compared with chow-fed animals. Although the presence of TG within lesions may be more labile than that of CE, aortic TG accumulation indicates that much lesion cholesterol was derived from TG-rich lipoproteins. 41 Furthermore, FAs derived from TG-rich lipoproteins, including VLDL, have been shown to significantly enhance inflammatory cytokine secretion from cultured macrophages; therefore, they may contribute to atherogenesis. 42 Naringenin significantly reduced TG and cholesterol accumulation in the aorta, indicating that naringenin attenuates the contribution of lipid derived from both VLDL and LDL to lesion formation.
Naringenin not only prevents VLDL overproduction and dyslipidemia but corrects other features of the metabolic syndrome, including obesity, glucose intolerance, and insulin resistance, which are associated with accelerated atherogenesis. 43 The roles of insulin resistance and glucose metabolism in lesion formation are difficult to dissect from the impact of dyslipidemia. In fat-fed C57BL/6 mice, insulin levels are not associated with atherosclerosis susceptibility. 44 In insulin-resistant ob/ob mice, the Western diet does not induce atherosclerosis unless the mice are crossed with Ldlr Ϫ/Ϫ mice to exaggerate the dyslipidemia. 45 However, in ob/ob Ldlr Ϫ/Ϫ mice fed a Western diet, plasma insulin levels predict atherosclerotic lesion area, whereas lesion burden was not associated with variation in plasma cholesterol or lipoprotein lipid levels. 46 In vitro, insulin-resistant macrophages are more susceptible to apoptosis on free cholesterol loading. 47 In the present study, the prevention of hyperinsulinemia by naringenin likely has its primary impact on atherosclerosis through the prevention of insulin-stimulated lipogenesis and the subsequent inhibition of VLDL overproduction. The overproduction of hepatic VLDL in insulin-resistant states is contributed to by increases in FFA flux from visceral adipose tissue, increased uptake of remnants, and hyperinsulinemia-stimulated de novo lipogenesis. 48 In liver, de novo lipogenesis via activation of the transcription factor sterol regulatory element binding protein 1c becomes hypersensitive to increased plasma insulin levels, contributing significantly to VLDL overproduction. 49 Recently, it was demonstrated that in Western-fed Ldlr Ϫ/Ϫ mice, naringenin prevented hyperinsulinemia, which was associated with decreased hepatic sterol regulatory element binding protein 1c-stimulated FA and TG synthesis, leading to decreased VLDL secretion. 26 The concept that hyperinsulinemia contributes to atherogenesis through VLDL overproduction is consistent with studies in Western-fed Ldlr Ϫ/Ϫ mice in which hepatic insulin receptors are low (L1 B6 Ldlr Ϫ/Ϫ ), sterol regulatory element binding protein 1c levels are decreased, VLDL-TG secretion into plasma is reduced, and atherosclerosis is markedly attenuated, despite severe hyperinsulinemia. 50 Naringenin prevented adipose accumulation and adipocyte hypertrophy induced by the Western diet. In fat-fed Ldlr Ϫ/Ϫ mice, inflammatory changes in adipose tissue are associated with insulin resistance and systemic inflammation and contribute to increased atherosclerosis in this mouse model. 51 We observed no changes in plasma adiponectin or interleukin 6 level in Western-fed mice compared with either chow-fed or naringenin-treated mice, suggesting that any inflammation in adipose tissue, if present, is localized. It is possible that this is related to the relatively low dietary cholesterol content (0.05% cholesterol) of the Western diet. A previous study by Subramanian et al 51 demonstrated that macrophage infiltration into adipose tissue and increased expression and secretion of inflammatory mediators were readily observed in mice fed a 0.2% cholesterol-containing Western diet.
Morphometric analyses demonstrated that lesions in naringenin-treated mice were less advanced, characterized by reduced infiltration of SMCs and deposition of collagen. In addition to the prevention of dyslipidemia and insulin resistance, naringenin may contribute to reduced lesion area and changes in lesion composition through direct effects within the vessel wall. For example, it is possible that naringenin influences endothelial function, oxidation of lipoproteins, foam cell formation, or cellular apoptosis, some of which are affected by other flavonoids or polyphenols. 19, 20, 52 However, the impact of naringenin on these parameters was not evaluated in the present study and, thus, requires further investigation.
In conclusion, these in vivo studies demonstrate that the citrus flavonoid naringenin ameliorates the dyslipidemia, hyperinsulinemia, and obesity in Western-fed Ldlr Ϫ/Ϫ mice, resulting in the prevention of atherosclerosis. Although other mechanisms may have contributed, our results suggest that in the fat-fed Ldlr Ϫ/Ϫ mouse, naringenin mediates its antiathero-genic effects through potent lipid lowering. These observations suggest that naturally derived compounds may have powerful pharmacological properties and identify targets to correct metabolic abnormalities and attenuate atherosclerosis in insulin-resistant states.
